Histrelin Implants for Suppression of Puberty in Youth with Gender Dysphoria: A Comparison of 50 mcg/Day (Vantas) and 65 mcg/Day (SupprelinLA)

Purpose: Development of incongruent secondary sex characteristics in transgender youth can intensify or trigger the onset of gender dysphoria. Guidelines from professional organizations recommend gonadotropin-releasing hormone agonists, including histrelin implants (Vantas and SupprelinLA) to suppre...

Descripción completa

Detalles Bibliográficos
Autores principales: Olson-Kennedy, Johanna, Streeter, Laer H., Garofalo, Robert, Chan, Yee-Ming, Rosenthal, Stephen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906230/
https://www.ncbi.nlm.nih.gov/pubmed/33644320
http://dx.doi.org/10.1089/trgh.2020.0055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906230/
https://www.ncbi.nlm.nih.gov/pubmed/33644320
http://dx.doi.org/10.1089/trgh.2020.0055

Ejemplares similares